skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Tenofovir: A new option for the treatment of chronic hepatitis B

Review

(2781) Views  (1239) Full article downloads

Authors: Walid S Ayoub

Published Date September 2009 Volume 2009:1 Pages 5 - 10
DOI: http://dx.doi.org/10.2147/VAAT.S4712

Walid S Ayoub

Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University Medical Center, Stanford, CA, USA

Abstract: Treatment of chronic hepatitis B (CHB) continues to evolve. Over the last decade, progressively lower levels of serum HBV DNA have been used as a threshold for treatment. A high degree of antiviral potency and a low rate of resistance are the two most important factors in the choice of an agent for therapy of CHB. Achieving rapid viral suppression is also a key factor in choosing the first line of therapy. Swift and potent viral suppression decreases the risk of hepatic decompensation, development of hepatocellular carcinoma and subsequent need for liver transplantation. Currently, entecavir and tenofovir are the most potent nucleoside and nucleotide analogs with the lowest rate of resistance in treatment-naïve patients. This review will evaluate the safety and efficacy of the use of tenofovir disoproxil fumarate, the newest agent, for the treatment of patients with CHB.

Keywords: tenofovir, TDF, chronic hepatitis B, resistance, safety








Readers of this article also read:

Berberine: metabolic and cardiovascular effects in preclinical and clinical trials
Potential renovascular hypertension, space missions, and the role of magnesium
Critical appraisal of the role of glucosamine and chondroitin in the management of osteoarthritis of the knee
Ego mechanisms of defense are associated with patients’ preference of treatment modality independent of psychological distress in end-stage renal disease
Can a gentamicin-specific chart reduce neonatal medication errors?
Nephroprotective action of glycosaminoglycans: why the pharmacological properties of sulodexide might be reconsidered
Dashboards in neonatology
Lyme disease: the next decade
Everolimus-eluting stents: update on current clinical studies
Metabolic pathway and distribution of superparamagnetic iron oxide nanoparticles: in vivo study
  • Testimonials

    "You do a tremendous job!!" Ruben Restrepo, The University of Texas Health Science Center at San Antonio